Royal Bank of Canada
RNXT icon

Royal Bank of Canada’s RenovoRx RNXT Stock Holding History

Royal Bank of Canada’s Portfolio RNXT Stock Details RNXT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-203
Closed – – 7350
2024
Q2 		$0 Buy
203
+70
+53% +$86 ﹤0.01% 7462
2024
Q1 		$0 Buy
133
+32
+32% +$46 ﹤0.01% 7509
2023
Q4 		$0 Buy
+101
New +$96 ﹤0.01% 7512

Other funds holding RNXT

Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
NPT
Nixon Peabody Trust Boston, Massachusetts $1.41B AUM 27.78% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
KAS
Kestra Advisory Services Austin, Texas $31B AUM 28.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Affinity Capital Advisors Berkeley, California $810M AUM 24.85% 1-Year Est. Return

Royal Bank of Canada's RNXT Position: Q3 2024 in Review

Royal Bank of Canada sold out of RenovoRx (RNXT) in Q3 2024, closing a stake of 203 shares.

Royal Bank of Canada first reported a position in RNXT in Q4 2023 and held it in 3 quarters. The position peaked at $0 in Q2 2024. 13 funds tracked by Wall St. Rank hold RNXT as of Q3 2024.

  • Royal Bank of Canada reported no remaining RenovoRx position as of Q3 2024 after selling out during the quarter.
  • Royal Bank of Canada sold 203 RenovoRx shares in Q3 2024.
  • Royal Bank of Canada first reported a position in RenovoRx in Q4 2023 and held it in 3 quarters.
  • Royal Bank of Canada's RenovoRx position peaked at $0 in Q2 2024.
  • 13 funds tracked by Wall St. Rank held RenovoRx as of Q3 2024.

Based on Royal Bank of Canada's 13F filing for Q3 2024, filed 14 Nov 2024.